Premium
Potassium Homeostasis During Angiotensin‐Converting Enzyme Inhibition with Enalapril
Author(s) -
Scandling John D.,
Izzo Joseph L.,
Pabico Rufino C.,
McKenna Barbara A.,
Radke Karen J.,
Ornt Daniel B.
Publication year - 1989
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1989.tb03255.x
Subject(s) - enalapril , homeostasis , angiotensin converting enzyme , potassium , enzyme , renin–angiotensin system , pharmacology , angiotensin ii , chemistry , medicine , endocrinology , biochemistry , blood pressure , organic chemistry
The effect of angiotensin‐converting enzyme (ACE) inhibition on renal and extrarenal potassium (K) regulation was examined. Six healthy men were studied in double‐blinded crossover fashion on placebo or enalapril, 80 mg/day. On day 4, the subjects were given an intravenous infusion of KCI and on day 5 an oral dose of 10% NH 4 Cl. Treatment with enalapril decreased plasma aldosterone and increased plasma renin activity (PRA), epinephrine and norepinephrine, but did not affect serum glucose, plasma insulin or basal plasma K. Maximal increases in plasma K during K infusion or NH 4 Cl ingestion were similar during enalapril and placebo treatment. With enalapril treatment urinary K excretion was unchanged following K loading but moderately reduced following NH 4 Cl loading. We conclude that ACE inhibition does not acutely impair K homeostasis in men with normal renal function.